Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1093/ndt/gfw453 http://scihub22266oqcxt.onion/10.1093/ndt/gfw453 C5410989!5410989!28339660     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Nephrol+Dial+Transplant 2017 ; 32 (3): 466-74 Nephropedia Template TP {{tp|p=28339660|t=2017. Eculizumab in secondary atypical haemolytic uraemic syndrome |pdf=|usr=}}{{28339660}} gab.com Text Eculizumab in secondary atypical haemolytic uraemic syndrome JO: Nephrol Dial Transplant http://www.kidney.de/pget.php?&tw=1&pmid=28339660 #FOAvip Background. Complement dysregulation occurs in thrombotic microangiopathies (TMAs) other than primary atypical haemolytic uraemic syndrome (aHUS). A few of these patients have been reported previously to be successfully treated with eculizumab.Methods. We identified 29 patients with so-called secondary aHUS who had received eculizumab at 11 Spanish nephrology centres. Primary outcome was TMA resolution, defined by a normalization of platelet count (>150 × 109/L) and haemoglobin, disappearance of all the markers of microangiopathic haemolytic anaemia (MAHA), and improvement of renal function, with a??25% reduction of serum creatinine from the onset of eculizumab administration.Results. Twenty-nine patients with secondary aHUS (15 drug-induced, 8 associated with systemic diseases, 2 with postpartum, 2 with cancer-related, 1 associated with acute humoral rejection and 1 with intestinal lymphangiectasia) were included in this study. The reason to initiate eculizumab treatment was worsening of renal function and persistence of TMA despite treatment of the TMA cause and plasmapheresis. All patients showed severe MAHA and renal function impairment (14 requiring dialysis) prior to eculizumab treatment and 11 presented severe extrarenal manifestations. A rapid resolution of the TMA was observed in 20 patients (68%), 15 of them showing a??50% serum creatinine reduction at the last follow-up. Comprehensive genetic and molecular studies in 22 patients identified complement pathogenic variants in only 2 patients. With these two exceptions, eculizumab was discontinued, after a median of 8 weeks of treatment, without the occurrence of aHUS relapses.Conclusion. Short treatment with eculizumab can result in a rapid improvement of patients with secondary aHUS in whom TMA has persisted and renal function worsened despite treatment of the TMA-inducing condition. Twit Text FOAVip Eculizumab in secondary atypical haemolytic uraemic syndrome ????Nephrol Dial Transplant http://www.kidney.de/pget.php?&tw=1&pmid=28339660 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28339660 #FOAvip English Wikipedia <ref>{{Cite pmid|28339660}}</ref> Eculizumab in secondary atypical haemolytic uraemic syndrome #MMPMID28339660 Cavero T; Rabasco C; López A; Román E; Ávila A; Sevillano Á; Huerta A; Rojas-Rivera J; Fuentes C; Blasco M; Jarque A; García A; Mendizabal S; Gavela E; Macía M; Quintana LF; María Romera A; Borrego J; Arjona E; Espinosa M; Portolés J; Gracia-Iguacel C; González-Parra E; Aljama P; Morales E; Cao M; Rodríguez de Córdoba S; Praga M Nephrol Dial Transplant 2017[Mar]; 32 (3): 466-74 PMID28339660show ga Background. Complement dysregulation occurs in thrombotic microangiopathies (TMAs) other than primary atypical haemolytic uraemic syndrome (aHUS). A few of these patients have been reported previously to be successfully treated with eculizumab.Methods. We identified 29 patients with so-called secondary aHUS who had received eculizumab at 11 Spanish nephrology centres. Primary outcome was TMA resolution, defined by a normalization of platelet count (>150 × 109/L) and haemoglobin, disappearance of all the markers of microangiopathic haemolytic anaemia (MAHA), and improvement of renal function, with a??25% reduction of serum creatinine from the onset of eculizumab administration.Results. Twenty-nine patients with secondary aHUS (15 drug-induced, 8 associated with systemic diseases, 2 with postpartum, 2 with cancer-related, 1 associated with acute humoral rejection and 1 with intestinal lymphangiectasia) were included in this study. The reason to initiate eculizumab treatment was worsening of renal function and persistence of TMA despite treatment of the TMA cause and plasmapheresis. All patients showed severe MAHA and renal function impairment (14 requiring dialysis) prior to eculizumab treatment and 11 presented severe extrarenal manifestations. A rapid resolution of the TMA was observed in 20 patients (68%), 15 of them showing a??50% serum creatinine reduction at the last follow-up. Comprehensive genetic and molecular studies in 22 patients identified complement pathogenic variants in only 2 patients. With these two exceptions, eculizumab was discontinued, after a median of 8 weeks of treatment, without the occurrence of aHUS relapses.Conclusion. Short treatment with eculizumab can result in a rapid improvement of patients with secondary aHUS in whom TMA has persisted and renal function worsened despite treatment of the TMA-inducing condition. äEculizumab in secondary atypical haemolytic uraemic syndrome (epmc).pdf DeepDyve Pubget Overpricing